← Back to patent-cliff list
Alpha-lactalbumin-oleic acid (Azanta)
Tier C — Watch / tradeAlpha-lactalbumin-oleic acid (Azanta)
Hamlet Pharma Ab
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Updating
Indications (approved)：Bladder cancer
Regional status
US
-
EU
Phase III
2026-09-17
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Alpha-lactalbumin-oleic acid (Azanta)?
Approved indications include: Bladder cancer.
When does the Alpha-lactalbumin-oleic acid (Azanta) patent expire?
No public expiry year is available for Alpha-lactalbumin-oleic acid (Azanta) yet; this page updates once verified.
How do I get a quote for Alpha-lactalbumin-oleic acid (Azanta) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-28